- JUST – EVOTEC BIOLOGICS AND SANDOZ JOIN FORCES TO DEVELOP AND MANUFACTURE A DEFINED PORTFOLIO OF BIOSIMILAR MOLECULES
- JUST – EVOTEC BIOLOGICS TO RECEIVE DOUBLE-DIGIT-MILLION UPFRONT, FUTURE PAYMENTS DEPENDENT ON SUCCESSFUL DEVELOPMENT PROGRESS OF US$ 640 M, ADDITIONAL UNDISCLOSED PAYMENTS DEPENDENT ON PROGRESS INTO COMMERCIAL MANUFACTURING AND EXERCISING THE S.POD OPTION
- THE PARTNERSHIP ASPIRES TO DISRUPT THE BIOSIMILARS MARKET WITH AFFORDABLE AND ACCESSIBLE HIGHEST-QUALITY MEDICINES FOR PATIENTS ACROSS THE GLOBE
- THE PARTNERSHIP IS FOUNDED ON JUST – EVOTEC BIOLOGICS’ AI-DRIVEN, FULLY INTEGRATED TECH PLATFORM AND CONTINUOUS MANUFACTURING COMBINED WITH SANDOZ’ LEADING BIOSIMILARS PIPELINE AND CAPABILITIES
- THE PARTNERSHIP INCLUDES AN OPTION FOR SANDOZ TO INLICENSE JUST – EVOTEC BIOLOGICS’ FULL TECH STACK, INJECTED IN ITS FULLY-OWNED ‘S.POD’ FACILITY TO EXPAND THE DISRUPTIVE DEVELOPMENT AND MANUFACTURING OF BIOSIMLARS IN THE LATTER PART OF THIS DECADE
Hamburg, Germany, and Seattle, WA, USA, 09 May 2023:
Evotec SE (Frankfurt Stock Exchange: EVT, Prime Standard, ISIN: DE0005664809; NASDAQ: EVO) and Sandoz AG, a division of Novartis (NASDAQ: NVS) today announced that Evotec’s Seattle-based subsidiary, Just – Evotec Biologics, Inc., launched a multi-year, long-term tech partnership with Sandoz for the immediate development and subsequent manufacturing of multiple biosimilars.